1
|
Besin V, Martriano Humardani F, Thalia Mulyanata L. Neurogenomics of Alzheimer's Disease (AD): An Asian Population Review. Clin Chim Acta 2023; 546:117389. [PMID: 37211175 DOI: 10.1016/j.cca.2023.117389] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Revised: 05/09/2023] [Accepted: 05/09/2023] [Indexed: 05/23/2023]
Abstract
Alzheimer's disease (AD) is on the rise worldwide. Generally, AD is considered neurodegenerative when the production and clearance of amyloid-β (Aβ) are imbalanced. Recent research on genome-wide association studies (GWAS) has been explosive; GWAS indicates a relationship between single nucleotide polymorphism (SNP) and AD. GWAS also reveals ethnic differences between Caucasians and Asians. This indicates that pathogenesis between ethnic groups is distinct. According to current scientific knowledge, AD is a disease with a complex pathogenesis that includes impaired neuronal cholesterol regulation, immunity regulation, neurotransmitters regulation, Aβ clearance, Aβ production, and vascular regulation. Here, we demonstrate the pathogenesis of AD in an Asian population and the SNP risk of AD for future AD screening before onset. According to our knowledge, this is the first review of Alzheimer's disease to demonstrate the pathogenesis of AD based on SNP in an Asian population.
Collapse
Affiliation(s)
- Valentinus Besin
- Faculty of Medicine, University of Surabaya, Surabaya 60292, Indonesia.
| | - Farizky Martriano Humardani
- Faculty of Medicine, University of Surabaya, Surabaya 60292, Indonesia; Magister in Biomedical Science Program, Faculty of Medicine Universitas Brawijaya, Malang 65112, Indonesia
| | | |
Collapse
|
2
|
Multi-Omic analyses characterize the ceramide/sphingomyelin pathway as a therapeutic target in Alzheimer's disease. Commun Biol 2022; 5:1074. [PMID: 36209301 PMCID: PMC9547905 DOI: 10.1038/s42003-022-04011-6] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Accepted: 09/20/2022] [Indexed: 11/09/2022] Open
Abstract
Dysregulation of sphingomyelin and ceramide metabolism have been implicated in Alzheimer's disease. Genome-wide and transcriptome-wide association studies have identified various genes and genetic variants in lipid metabolism that are associated with Alzheimer's disease. However, the molecular mechanisms of sphingomyelin and ceramide disruption remain to be determined. We focus on the sphingolipid pathway and carry out multi-omics analyses to identify central and peripheral metabolic changes in Alzheimer's patients, correlating them to imaging features. Our multi-omics approach is based on (a) 2114 human post-mortem brain transcriptomics to identify differentially expressed genes; (b) in silico metabolic flux analysis on context-specific metabolic networks identified differential reaction fluxes; (c) multimodal neuroimaging analysis on 1576 participants to associate genetic variants in sphingomyelin pathway with Alzheimer's disease pathogenesis; (d) plasma metabolomic and lipidomic analysis to identify associations of lipid species with dysregulation in Alzheimer's; and (e) metabolite genome-wide association studies to define receptors within the pathway as a potential drug target. We validate our hypothesis in amyloidogenic APP/PS1 mice and show prolonged exposure to fingolimod alleviated synaptic plasticity and cognitive impairment in mice. Our integrative multi-omics approach identifies potential targets in the sphingomyelin pathway and suggests modulators of S1P metabolism as possible candidates for Alzheimer's disease treatment.
Collapse
|
3
|
Yuan NY, Maung R, Xu Z, Han X, Kaul M. Arachidonic Acid Cascade and Eicosanoid Production Are Elevated While LTC4 Synthase Modulates the Lipidomics Profile in the Brain of the HIVgp120-Transgenic Mouse Model of NeuroHIV. Cells 2022; 11:2123. [PMID: 35805207 PMCID: PMC9265961 DOI: 10.3390/cells11132123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2022] [Revised: 06/24/2022] [Accepted: 06/26/2022] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND Combination antiretroviral therapy (cART) has transformed HIV infection from a terminal disease to a manageable chronic health condition, extending patients' life expectancy to that of the general population. However, the incidence of HIV-associated neurocognitive disorders (HANDs) has persisted despite virological suppression. Patients with HIV display persistent signs of immune activation and inflammation despite cART. The arachidonic acid (AA) cascade is an important immune response system responsible for both pro- and anti-inflammatory processes. METHODS Lipidomics, mRNA and Western blotting analysis provide valuable insights into the molecular mechanisms surrounding arachidonic acid metabolism and the resulting inflammation caused by perturbations thereof. RESULTS Here, we report the presence of inflammatory eicosanoids in the brains of a transgenic mouse model of NeuroHIV that expresses soluble HIV-1 envelope glycoprotein in glial cells (HIVgp120tg mice). Additionally, we report that the effect of LTC4S knockout in HIVgp120tg mice resulted in the sexually dimorphic transcription of COX- and 5-LOX-related genes. Furthermore, the absence of LTC4S suppressed ERK1/2 and p38 MAPK signaling activity in female mice only. The mass spectrometry-based lipidomic profiling of these mice reveals beneficial alterations to lipids in the brain. CONCLUSION Targeting the AA cascade may hold potential in the treatment of neuroinflammation observed in NeuroHIV and HANDs.
Collapse
Affiliation(s)
- Nina Y. Yuan
- Division of Biomedical Sciences, School of Medicine, University of California Riverside, 900 University Ave, Riverside, CA 92521, USA; (N.Y.Y.); (R.M.)
- Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
| | - Ricky Maung
- Division of Biomedical Sciences, School of Medicine, University of California Riverside, 900 University Ave, Riverside, CA 92521, USA; (N.Y.Y.); (R.M.)
- Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
| | - Ziying Xu
- Barshop Institute for Longevity and Aging Studies, University of Texas Health San Antonio, San Antonio, TX 78229, USA; (Z.X.); (X.H.)
| | - Xianlin Han
- Barshop Institute for Longevity and Aging Studies, University of Texas Health San Antonio, San Antonio, TX 78229, USA; (Z.X.); (X.H.)
- Department of Medicine-Diabetes, University of Texas Health San Antonio, San Antonio, TX 78229, USA
| | - Marcus Kaul
- Division of Biomedical Sciences, School of Medicine, University of California Riverside, 900 University Ave, Riverside, CA 92521, USA; (N.Y.Y.); (R.M.)
- Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
| |
Collapse
|
4
|
Signorelli P, Conte C, Albi E. The Multiple Roles of Sphingomyelin in Parkinson's Disease. Biomolecules 2021; 11:biom11091311. [PMID: 34572524 PMCID: PMC8469734 DOI: 10.3390/biom11091311] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2021] [Revised: 08/26/2021] [Accepted: 09/03/2021] [Indexed: 01/07/2023] Open
Abstract
Advances over the past decade have improved our understanding of the role of sphingolipid in the onset and progression of Parkinson's disease. Much attention has been paid to ceramide derived molecules, especially glucocerebroside, and little on sphingomyelin, a critical molecule for brain physiopathology. Sphingomyelin has been proposed to be involved in PD due to its presence in the myelin sheath and for its role in nerve impulse transmission, in presynaptic plasticity, and in neurotransmitter receptor localization. The analysis of sphingomyelin-metabolizing enzymes, the development of specific inhibitors, and advanced mass spectrometry have all provided insight into the signaling mechanisms of sphingomyelin and its implications in Parkinson's disease. This review describes in vitro and in vivo studies with often conflicting results. We focus on the synthesis and degradation enzymes of sphingomyelin, highlighting the genetic risks and the molecular alterations associated with Parkinson's disease.
Collapse
Affiliation(s)
- Paola Signorelli
- Biochemistry and Molecular Biology Laboratory, Health Sciences Department, University of Milan, 20142 Milan, Italy;
| | - Carmela Conte
- Department of Pharmaceutical Sciences, University of Perugia, 06126 Perugia, Italy;
| | - Elisabetta Albi
- Department of Pharmaceutical Sciences, University of Perugia, 06126 Perugia, Italy;
- Correspondence:
| |
Collapse
|
5
|
Fote G, Wu J, Mapstone M, Macciardi F, Fiandaca MS, Federoff HJ. Plasma Sphingomyelins in Late-Onset Alzheimer's Disease. J Alzheimers Dis 2021; 83:1161-1171. [PMID: 34397408 PMCID: PMC9788856 DOI: 10.3233/jad-200871] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
BACKGROUND Altered plasma levels of sphingolipids, including sphingomyelins (SM), have been found in mouse models of Alzheimer's disease (AD) and in AD patient plasma samples. OBJECTIVE This study assesses fourteen plasma SM species in a late-onset AD (LOAD) patient cohort (n = 138). METHODS Specimens from control, preclinical, and symptomatic subjects were analyzed using targeted mass-spectrometry-based metabolomic methods. RESULTS Total plasma SM levels were not significantly affected by age or cognitive status. However, one metabolite that has been elevated in manifest AD in several recent studies, SM OHC14:1, was reduced significantly in pre-clinical AD and MCI relative to normal controls. CONCLUSION We recommend additional comprehensive plasma lipidomics in experimental and clinical biospecimens related to LOAD that might advance the utility of plasma sphingomyelin levels in molecular phenotyping and interpretations of pathobiological mechanisms.
Collapse
Affiliation(s)
- Gianna Fote
- UC Irvine Department of Biological Chemistry, Irvine, CA, USA,Correspondence to: Gianna M. Fote, UC Irvine School of Medicine, 385 S. Manchester Ave, Unit 2096, Orange, CA 92686, USA. Tel.: +1 310 924 4415; . and Howard Federoff, MD, PhD, Distinguished Professor, Neurology, UC Irvine School of Medicine, Orange, CA 92686, USA. Tel.: +1 240 281 2598;
| | - Jie Wu
- UC Irvine Department of Biological Chemistry, Irvine, CA, USA,UC Irvine Center for Complex Biological Systems, Irvine, CA, USA
| | | | - Fabio Macciardi
- Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, CA, USA
| | - Massimo S. Fiandaca
- Translational Laboratory and Biorepository, Department of Neurology, University of California Irvine School of Medicine, Irvine, CA, USA,Department of Neurological Surgery, University of California Irvine School of Medicine, Irvine, CA, USA,Department of Anatomy & Neurobiology, University of California Irvine School of Medicine, Irvine, CA, USA
| | - Howard J. Federoff
- UC Irvine Department of Neurology, Irvine, CA, USA,Correspondence to: Gianna M. Fote, UC Irvine School of Medicine, 385 S. Manchester Ave, Unit 2096, Orange, CA 92686, USA. Tel.: +1 310 924 4415; . and Howard Federoff, MD, PhD, Distinguished Professor, Neurology, UC Irvine School of Medicine, Orange, CA 92686, USA. Tel.: +1 240 281 2598;
| |
Collapse
|
6
|
Cheng Y, Saville L, Gollen B, Isaac C, Belay A, Mehla J, Patel K, Thakor N, Mohajerani MH, Zovoilis A. Increased processing of SINE B2 ncRNAs unveils a novel type of transcriptome deregulation in amyloid beta neuropathology. eLife 2020; 9:61265. [PMID: 33191914 PMCID: PMC7717908 DOI: 10.7554/elife.61265] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2020] [Accepted: 11/15/2020] [Indexed: 12/18/2022] Open
Abstract
The functional importance of many non-coding RNAs (ncRNAs) generated by repetitive elements and their connection with pathologic processes remains elusive. B2 RNAs, a class of ncRNAs of the B2 family of SINE repeats, mediate through their processing the transcriptional activation of various genes in response to stress. Here, we show that this response is dysfunctional during amyloid beta toxicity and pathology in the mouse hippocampus due to increased levels of B2 RNA processing, leading to constitutively elevated B2 RNA target gene expression and high Trp53 levels. Evidence indicates that Hsf1, a master regulator of stress response, mediates B2 RNA processing in hippocampal cells and is activated during amyloid toxicity, accelerating the processing of SINE RNAs and gene hyper-activation. Our study reveals that in mouse, SINE RNAs constitute a novel pathway deregulated in amyloid beta pathology, with potential implications for similar cases in the human brain, such as Alzheimer’s disease (AD).
Collapse
Affiliation(s)
- Yubo Cheng
- Department of Chemistry and Biochemistry, University of Lethbridge, Lethbridge, Canada.,Southern Alberta Genome Sciences Centre, University of Lethbridge, Lethbridge, Canada.,Canadian Centre for Behavioral Neuroscience, University of Lethbridge, Lethbridge, Canada.,Alberta RNA Research and Training Institute, University of Lethbridge, Lethbridge, Canada
| | - Luke Saville
- Department of Chemistry and Biochemistry, University of Lethbridge, Lethbridge, Canada.,Southern Alberta Genome Sciences Centre, University of Lethbridge, Lethbridge, Canada.,Canadian Centre for Behavioral Neuroscience, University of Lethbridge, Lethbridge, Canada.,Alberta RNA Research and Training Institute, University of Lethbridge, Lethbridge, Canada
| | - Babita Gollen
- Department of Chemistry and Biochemistry, University of Lethbridge, Lethbridge, Canada.,Southern Alberta Genome Sciences Centre, University of Lethbridge, Lethbridge, Canada.,Canadian Centre for Behavioral Neuroscience, University of Lethbridge, Lethbridge, Canada.,Alberta RNA Research and Training Institute, University of Lethbridge, Lethbridge, Canada
| | - Christopher Isaac
- Department of Chemistry and Biochemistry, University of Lethbridge, Lethbridge, Canada.,Southern Alberta Genome Sciences Centre, University of Lethbridge, Lethbridge, Canada.,Canadian Centre for Behavioral Neuroscience, University of Lethbridge, Lethbridge, Canada.,Alberta RNA Research and Training Institute, University of Lethbridge, Lethbridge, Canada
| | - Abel Belay
- Department of Chemistry and Biochemistry, University of Lethbridge, Lethbridge, Canada.,Southern Alberta Genome Sciences Centre, University of Lethbridge, Lethbridge, Canada.,Canadian Centre for Behavioral Neuroscience, University of Lethbridge, Lethbridge, Canada.,Alberta RNA Research and Training Institute, University of Lethbridge, Lethbridge, Canada
| | - Jogender Mehla
- Canadian Centre for Behavioral Neuroscience, University of Lethbridge, Lethbridge, Canada
| | - Kush Patel
- Department of Chemistry and Biochemistry, University of Lethbridge, Lethbridge, Canada.,Southern Alberta Genome Sciences Centre, University of Lethbridge, Lethbridge, Canada.,Canadian Centre for Behavioral Neuroscience, University of Lethbridge, Lethbridge, Canada
| | - Nehal Thakor
- Department of Chemistry and Biochemistry, University of Lethbridge, Lethbridge, Canada.,Southern Alberta Genome Sciences Centre, University of Lethbridge, Lethbridge, Canada.,Canadian Centre for Behavioral Neuroscience, University of Lethbridge, Lethbridge, Canada
| | - Majid H Mohajerani
- Canadian Centre for Behavioral Neuroscience, University of Lethbridge, Lethbridge, Canada
| | - Athanasios Zovoilis
- Department of Chemistry and Biochemistry, University of Lethbridge, Lethbridge, Canada.,Southern Alberta Genome Sciences Centre, University of Lethbridge, Lethbridge, Canada.,Canadian Centre for Behavioral Neuroscience, University of Lethbridge, Lethbridge, Canada.,Alberta RNA Research and Training Institute, University of Lethbridge, Lethbridge, Canada
| |
Collapse
|
7
|
Zhao Y, Zhu H, Lu Z, Knickmeyer RC, Zou F. Structured Genome-Wide Association Studies with Bayesian Hierarchical Variable Selection. Genetics 2019; 212:397-415. [PMID: 31010934 PMCID: PMC6553832 DOI: 10.1534/genetics.119.301906] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2019] [Accepted: 04/08/2019] [Indexed: 02/04/2023] Open
Abstract
It becomes increasingly important in using genome-wide association studies (GWAS) to select important genetic information associated with qualitative or quantitative traits. Currently, the discovery of biological association among SNPs motivates various strategies to construct SNP-sets along the genome and to incorporate such set information into selection procedure for a higher selection power, while facilitating more biologically meaningful results. The aim of this paper is to propose a novel Bayesian framework for hierarchical variable selection at both SNP-set (group) level and SNP (within group) level. We overcome a key limitation of existing posterior updating scheme in most Bayesian variable selection methods by proposing a novel sampling scheme to explicitly accommodate the ultrahigh-dimensionality of genetic data. Specifically, by constructing an auxiliary variable selection model under SNP-set level, the new procedure utilizes the posterior samples of the auxiliary model to subsequently guide the posterior inference for the targeted hierarchical selection model. We apply the proposed method to a variety of simulation studies and show that our method is computationally efficient and achieves substantially better performance than competing approaches in both SNP-set and SNP selection. Applying the method to the Alzheimers Disease Neuroimaging Initiative (ADNI) data, we identify biologically meaningful genetic factors under several neuroimaging volumetric phenotypes. Our method is general and readily to be applied to a wide range of biomedical studies.
Collapse
Affiliation(s)
- Yize Zhao
- Department of Healthcare Policy and Research, Cornell University Weill Cornell, New York, New York 10065
| | - Hongtu Zhu
- Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina 27599
| | - Zhaohua Lu
- Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105
| | - Rebecca C Knickmeyer
- Department of Pediatrics and Human Development, Michigan State University, East Lansing, Michigan 48824
| | - Fei Zou
- Department of Biostatistics, University of Florida, Gainesville, Florida 32611
| |
Collapse
|
8
|
Lu MH, Ji WL, Xu DE, Yao PP, Zhao XY, Wang ZT, Fang LP, Huang R, Lan LJ, Chen JB, Wang TH, Cheng LH, Xu RX, Liu CF, Puglielli L, Ma QH. Inhibition of sphingomyelin synthase 1 ameliorates alzheimer-like pathology in APP/PS1 transgenic mice through promoting lysosomal degradation of BACE1. Exp Neurol 2018; 311:67-79. [PMID: 30243987 DOI: 10.1016/j.expneurol.2018.09.012] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2018] [Revised: 08/12/2018] [Accepted: 09/17/2018] [Indexed: 12/11/2022]
Abstract
Sphingolipids emerge as essential modulators in the etiology of Alzheimer's disease (AD) with unclear mechanisms. Elevated levels of SM synthase 1 (SMS1), which catalyzes the synthesis of SM from ceramide and phosphatidylcholine, have been observed in the brains of Alzheimer's disease (AD), where expression of β-site APP cleaving enzyme 1 (BACE1), a rate limiting enzyme in amyloid-β (Aβ) generation, are upregulated. In the present study, we show knockdown of SMS1 via andeno associated virus (serotype 8, AAV8) in the hippocampus of APP/PS1 transgenic mice, attenuates the densities of Aβ plaques, neuroinflammation, synaptic loss and thus rescuing cognitive deficits of these transgenic mice. We further describe that knockdown or inhibition of SMS1 decreases BACE1 stability, which is accompanied with decreased BACE1 levels in the Golgi, whereas enhanced BACE1 levels in the early endosomes and the lysosomes. The reduction of BACE1 levels induced by knockdown or inhibition of SMS1 is prevented by inhibition of lysosomes. Therefore, knockdown or inhibition of SMS1 promotes lysosomal degradation of BACE1 via modulating the intracellular trafficking of BACE1. Knockdown of SMS1 attenuates AD-like pathology through promoting lysosomal degradation of BACE1.
Collapse
Affiliation(s)
- Mei-Hong Lu
- Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho- Diseases, Institute of Neuroscience, Soochow University, Suzhou 215004, China; Department of Neurology and Suzhou Clinical Research Center of Neurological Disease, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China
| | - Wen-Li Ji
- Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho- Diseases, Institute of Neuroscience, Soochow University, Suzhou 215004, China; Department of Neurology and Suzhou Clinical Research Center of Neurological Disease, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China
| | - De-En Xu
- Department of Neurology, The Second People's Hospital of Wuxi, Wuxi 214002, China
| | - Pei-Pei Yao
- Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho- Diseases, Institute of Neuroscience, Soochow University, Suzhou 215004, China; Department of Neurology and Suzhou Clinical Research Center of Neurological Disease, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China
| | - Xiu-Yun Zhao
- Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho- Diseases, Institute of Neuroscience, Soochow University, Suzhou 215004, China; Department of Neurology and Suzhou Clinical Research Center of Neurological Disease, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China
| | - Zhao-Tao Wang
- Affiliated Bayi Brain Hospital, Military General Hospital of Beijing PLA, Southern Medical University, Beijing 100700, China
| | - Li-Pao Fang
- Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho- Diseases, Institute of Neuroscience, Soochow University, Suzhou 215004, China; Department of Neurology and Suzhou Clinical Research Center of Neurological Disease, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China
| | - Rui Huang
- Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho- Diseases, Institute of Neuroscience, Soochow University, Suzhou 215004, China; Department of Neurology and Suzhou Clinical Research Center of Neurological Disease, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China
| | - Li-Jun Lan
- Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho- Diseases, Institute of Neuroscience, Soochow University, Suzhou 215004, China; Department of Neurology and Suzhou Clinical Research Center of Neurological Disease, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China
| | - Ji-Bo Chen
- Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho- Diseases, Institute of Neuroscience, Soochow University, Suzhou 215004, China; Department of Neurology and Suzhou Clinical Research Center of Neurological Disease, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China
| | - Ting-Hua Wang
- Institute of Neuroscience, Kunming Medical University, Kunming 650500, China
| | - Li-Hua Cheng
- Affiliated Bayi Brain Hospital, Military General Hospital of Beijing PLA, Southern Medical University, Beijing 100700, China
| | - Ru-Xiang Xu
- Affiliated Bayi Brain Hospital, Military General Hospital of Beijing PLA, Southern Medical University, Beijing 100700, China
| | - Chun-Feng Liu
- Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho- Diseases, Institute of Neuroscience, Soochow University, Suzhou 215004, China; Department of Neurology and Suzhou Clinical Research Center of Neurological Disease, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China
| | - Luigi Puglielli
- Department of Medicine and Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison, Madison, WI 53705, USA
| | - Quan-Hong Ma
- Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho- Diseases, Institute of Neuroscience, Soochow University, Suzhou 215004, China; Department of Neurology and Suzhou Clinical Research Center of Neurological Disease, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China; Affiliated Bayi Brain Hospital, Military General Hospital of Beijing PLA, Southern Medical University, Beijing 100700, China.
| |
Collapse
|
9
|
Brandán YR, Guaytima EDV, Favale NO, Pescio LG, Sterin-Speziale NB, Márquez MG. The inhibition of sphingomyelin synthase 1 activity induces collecting duct cells to lose their epithelial phenotype. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH 2017; 1865:309-322. [PMID: 29128370 DOI: 10.1016/j.bbamcr.2017.11.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/16/2017] [Revised: 10/30/2017] [Accepted: 11/07/2017] [Indexed: 12/20/2022]
Abstract
Epithelial tissue requires that cells attach to each other and to the extracellular matrix by the assembly of adherens junctions (AJ) and focal adhesions (FA) respectively. We have previously shown that, in renal papillary collecting duct (CD) cells, both AJ and FA are located in sphingomyelin (SM)-enriched plasma membrane microdomains. In the present work, we investigated the involvement of SM metabolism in the preservation of the epithelial cell phenotype and tissue organization. To this end, primary cultures of renal papillary CD cells were performed. Cultured cells preserved the fully differentiated epithelial phenotype as reflected by the presence of primary cilia. Cells were then incubated for 24h with increasing concentrations of D609, a SM synthase (SMS) inhibitor. Knock-down experiments silencing SMS 1 and 2 were also performed. By combining biochemical and immunofluorescence studies, we found experimental evidences suggesting that, in CD cells, SMS 1 activity is essential for the preservation of cell-cell adhesion structures and therefore for the maintenance of CD tissue/tubular organization. The inhibition of SMS 1 activity induced CD cells to lose their epithelial phenotype and to undergo an epithelial-mesenchymal transition (EMT) process.
Collapse
Affiliation(s)
- Yamila Romina Brandán
- Instituto de Investigaciones en Ciencias de la Salud Humana (IICSHUM), Universidad Nacional de La Rioja, Av. Luis Vernet 1000, 5300 La Rioja, Argentina
| | - Edith Del Valle Guaytima
- Instituto de Investigaciones en Ciencias de la Salud Humana (IICSHUM), Universidad Nacional de La Rioja, Av. Luis Vernet 1000, 5300 La Rioja, Argentina
| | - Nicolás Octavio Favale
- Instituto de Química y Físico-Química Biológica (IQUIFIB) -CONICET, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, C1113AAD Buenos Aires, Argentina; Cátedra de Biología Celular, Departamento de Ciencias Biológicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, C1113AAD Buenos Aires, Argentina
| | - Lucila Gisele Pescio
- Instituto de Química y Físico-Química Biológica (IQUIFIB) -CONICET, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, C1113AAD Buenos Aires, Argentina; Cátedra de Biología Celular, Departamento de Ciencias Biológicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, C1113AAD Buenos Aires, Argentina
| | - Norma B Sterin-Speziale
- Instituto de Química y Físico-Química Biológica (IQUIFIB) -CONICET, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, C1113AAD Buenos Aires, Argentina.
| | - María Gabriela Márquez
- Instituto de Investigaciones en Ciencias de la Salud Humana (IICSHUM), Universidad Nacional de La Rioja, Av. Luis Vernet 1000, 5300 La Rioja, Argentina.
| |
Collapse
|
10
|
Kato M, Hammam MAS, Taniguchi T, Suga Y, Monde K. What Is the True Structure of D609, a Widely Used Lipid Related Enzyme Inhibitor? Org Lett 2016; 18:768-71. [DOI: 10.1021/acs.orglett.6b00025] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Mikako Kato
- Graduate
School of Life Science and ‡Faculty of Advanced Life Science,
Frontier Research Center for Post-Genome Science and Technology, Hokkaido University, Kita 21 Nishi 11, Sapporo 001-0021, Japan
| | - Mostafa A. S. Hammam
- Graduate
School of Life Science and ‡Faculty of Advanced Life Science,
Frontier Research Center for Post-Genome Science and Technology, Hokkaido University, Kita 21 Nishi 11, Sapporo 001-0021, Japan
| | - Tohru Taniguchi
- Graduate
School of Life Science and ‡Faculty of Advanced Life Science,
Frontier Research Center for Post-Genome Science and Technology, Hokkaido University, Kita 21 Nishi 11, Sapporo 001-0021, Japan
| | - Yoshiko Suga
- Graduate
School of Life Science and ‡Faculty of Advanced Life Science,
Frontier Research Center for Post-Genome Science and Technology, Hokkaido University, Kita 21 Nishi 11, Sapporo 001-0021, Japan
| | - Kenji Monde
- Graduate
School of Life Science and ‡Faculty of Advanced Life Science,
Frontier Research Center for Post-Genome Science and Technology, Hokkaido University, Kita 21 Nishi 11, Sapporo 001-0021, Japan
| |
Collapse
|
11
|
Fonteh AN, Ormseth C, Chiang J, Cipolla M, Arakaki X, Harrington MG. Sphingolipid metabolism correlates with cerebrospinal fluid Beta amyloid levels in Alzheimer's disease. PLoS One 2015; 10:e0125597. [PMID: 25938590 PMCID: PMC4418746 DOI: 10.1371/journal.pone.0125597] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2014] [Accepted: 03/24/2015] [Indexed: 12/14/2022] Open
Abstract
Sphingolipids are important in many brain functions but their role in Alzheimer’s disease (AD) is not completely defined. A major limit is availability of fresh brain tissue with defined AD pathology. The discovery that cerebrospinal fluid (CSF) contains abundant nanoparticles that include synaptic vesicles and large dense core vesicles offer an accessible sample to study these organelles, while the supernatant fluid allows study of brain interstitial metabolism. Our objective was to characterize sphingolipids in nanoparticles representative of membrane vesicle metabolism, and in supernatant fluid representative of interstitial metabolism from study participants with varying levels of cognitive dysfunction. We recently described the recruitment, diagnosis, and CSF collection from cognitively normal or impaired study participants. Using liquid chromatography tandem mass spectrometry, we report that cognitively normal participants had measureable levels of sphingomyelin, ceramide, and dihydroceramide species, but that their distribution differed between nanoparticles and supernatant fluid, and further differed in those with cognitive impairment. In CSF from AD compared with cognitively normal participants: a) total sphingomyelin levels were lower in nanoparticles and supernatant fluid; b) levels of ceramide species were lower in nanoparticles and higher in supernatant fluid; c) three sphingomyelin species were reduced in the nanoparticle fraction. Moreover, three sphingomyelin species in the nanoparticle fraction were lower in mild cognitive impairment compared with cognitively normal participants. The activity of acid, but not neutral sphingomyelinase was significantly reduced in the CSF from AD participants. The reduction in acid sphingomylinase in CSF from AD participants was independent of depression and psychotropic medications. Acid sphingomyelinase activity positively correlated with amyloid β42 concentration in CSF from cognitively normal but not impaired participants. In dementia, altered sphingolipid metabolism, decreased acid sphingomyelinase activity and its lost association with CSF amyloid β42 concentration, underscores the potential of sphingolipids as disease biomarkers, and acid sphingomyelinase as a target for AD diagnosis and/or treatment.
Collapse
Affiliation(s)
- Alfred N. Fonteh
- Molecular Neurology Program, Huntington Medical Research Institutes, 99 N El Molino Ave, Pasadena, California, United Sates of America
- * E-mail:
| | - Cora Ormseth
- Molecular Neurology Program, Huntington Medical Research Institutes, 99 N El Molino Ave, Pasadena, California, United Sates of America
| | - Jiarong Chiang
- Molecular Neurology Program, Huntington Medical Research Institutes, 99 N El Molino Ave, Pasadena, California, United Sates of America
| | - Matthew Cipolla
- Molecular Neurology Program, Huntington Medical Research Institutes, 99 N El Molino Ave, Pasadena, California, United Sates of America
| | - Xianghong Arakaki
- Molecular Neurology Program, Huntington Medical Research Institutes, 99 N El Molino Ave, Pasadena, California, United Sates of America
| | - Michael G. Harrington
- Molecular Neurology Program, Huntington Medical Research Institutes, 99 N El Molino Ave, Pasadena, California, United Sates of America
| |
Collapse
|
12
|
Sudarkina OY, Filippenkov IB, Brodsky IB, Limborska SA, Dergunova LV. Comparative analysis of sphingomyelin synthase 1 gene expression at the transcriptional and translational levels in human tissues. Mol Cell Biochem 2015; 406:91-9. [PMID: 25912551 DOI: 10.1007/s11010-015-2427-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2014] [Accepted: 04/22/2015] [Indexed: 12/18/2022]
Abstract
Sphingomyelin synthase 1 (SMS1) catalyses the biosynthesis of sphingomyelin in eukaryotic cells. We have previously determined the structure of the SGMS1 gene encoding this enzyme and a number of its alternative transcripts. Here, we describe a study of the expression of the full-length SMS1 protein and the sum of the alternative transcripts encoding this protein in human tissues. The SMS1 protein and mRNA levels in tissues differed significantly and were not correlated, implying the active post-transcriptional regulation of SMS1 protein expression. The putative truncated isoforms of the SMS1 protein, which are encoded by a number of alternative transcripts, were not detected by immunoblotting and thus may be absent or present in only small amounts.
Collapse
Affiliation(s)
- Olga Yu Sudarkina
- Human Molecular Genetics Department, Institute of Molecular Genetics, Russian Academy of Sciences, Moscow, 123182, Russia,
| | | | | | | | | |
Collapse
|
13
|
Lim WLF, Martins IJ, Martins RN. The involvement of lipids in Alzheimer's disease. J Genet Genomics 2014; 41:261-74. [PMID: 24894353 DOI: 10.1016/j.jgg.2014.04.003] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2013] [Revised: 04/11/2014] [Accepted: 04/15/2014] [Indexed: 12/14/2022]
Abstract
It has been estimated that Alzheimer's disease (AD), the most common form of dementia, will affect approximately 81 million individuals by 2040. To date, the actual cause and cascade of events in the progression of this disease have not been fully determined. Furthermore, there is currently no definitive blood test or simple diagnostic method for AD. Considerable efforts have been put into proteomic approaches to develop a diagnostic blood test, but to date these efforts have not been successful. More recently, there has been a stronger focus on lipidomic studies in the hope of increasing our understanding of the underlying mechanisms leading to AD and developing an AD blood test. It is well known that the strongest genetic risk factor for AD is the ε4 variant of apolipoprotein E (APOE). Evidence suggests that the ApoE protein, a major lipid transporter, plays a key role in the pathogenesis of AD, and its role in both normal and aberrant lipid metabolism warrants further extensive investigation. Here, we review ApoE-lipid interactions, as well as the roles that lipids may play in the pathogenesis of AD.
Collapse
Affiliation(s)
- Wei Ling Florence Lim
- School of Medical Sciences, Edith Cowan University, Joondalup 6027, Australia; Centre of Excellence in Alzheimer's Disease Research and Care, Joondalup 6027, Australia
| | - Ian James Martins
- School of Medical Sciences, Edith Cowan University, Joondalup 6027, Australia; Centre of Excellence in Alzheimer's Disease Research and Care, Joondalup 6027, Australia
| | - Ralph Nigel Martins
- School of Medical Sciences, Edith Cowan University, Joondalup 6027, Australia; Centre of Excellence in Alzheimer's Disease Research and Care, Joondalup 6027, Australia; McCusker Foundation for Alzheimer's Disease Research Inc., Suite 22, Hollywood Medical Centre, Nedlands 6009, Australia; School of Psychiatry and Clinical Neurosciences, The University of Western Australia, Nedlands 6009, Australia.
| |
Collapse
|